辛伐他汀治疗血脂正常急性冠脉综合征的临床试验
《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]
- 期数:
- 2010年第5期
- 页码:
- 733-735
- 栏目:
- 临床研究
- 出版日期:
- 2010-06-22
文章信息/Info
- Title:
- Clinical study on treatment of acute coronary syndrome with simvastatin in ortholiposis patients
- Author(s):
- FU Zhong-yang1; LIN Zhao-heng2
- 1.Department of Internal Medicine, Hospital of PAP Kunming Frontier Defense School, Kunming, 650214, Yunnan, China; 2.Department of Cardiology, Hospital of Xishuangbanna Prefecture, Jinghong 666100, Yunnan, China
- 分类号:
- R541.4
- DOI:
- -
- 文献标识码:
- A
- 摘要:
- 目的: 探讨辛伐他汀在治疗血脂正常的急性冠脉综合征（ACS）中的可行性、有效性和安全性。方法： 239例ACS患者，随机分为试药组（n=115）和对照组（n=124），试药组在对照组常规治疗的基础上加用辛伐他汀口服20 mg/d治疗。出院后继续口服辛伐他汀6个月。所有患者进行随访。观察两组病例用药前后主要心血管事件的发生率。结果： 用药6个月后试药组发生心血管事件18例（15.6%），对照组发生心血管事件49例（39.5%），两组间的差异具有显著性意义（P<0.05）；试药组血清总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）及C-反应蛋白（CRP）水平，与治疗前比较显著降低，差异具有显著性意义（P<0.05）。两组不良反应比较差异无显著性意义。结论： 辛伐他汀治疗血脂正常的ACS 疗效确切，无明显副作用。
- Abstract:
- AIM: To explore the effectiveness and safety of simvastatin in the treatment of ortholiposis acute coronary syndrome (ACS). METHODS: Two hundred and thirty-nine ACS patients were randomly divided into treatment group (n=115) and control group (n=124), and an additional 20 mg/day simvastatin was administered orally in the treatment group in addition to the same normal treatment of the control group. Patients in the treatment group continued to take simvastatin orally for 6 months after hospital discharge and follow-up visits were done for all patients. The incidence rates of major cardiovascular events of the two groups before and after taking simvastatin were observed. RESULTS: Eighteen cardiovascular events (15.65%) were found in the treatment group after taking simvastatin for 6 months, whereas 49 cardiovascular events (39.52%) were found in the control group, with significant difference between groups (P<0.05). Total cholesterol (TC) in serum, low-density lipoprotein cholesterol (LDL-C) and C-reactive protein (CRP) after treatment were significantly lower than those before treatment (P<0.05). No significant difference was found in adverse reactions between groups (P>0.05). CONCLUSION: Simvastatin is effective and safe in the treatment of ortholiposis ACS.
参考文献/References
［1］李建军. 他汀类药物治疗急性冠脉综合症的抗炎机制［J］. 临床内科杂志， 2006， 23（1）：8-11.
［2］Li JJ, Fang CH. Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosis［J］. Med Hypotheses, 2004, 63（1）:100-102.
［3］Li JJ, Fang CH, Wang C, et al. Effects of simvastatin on exercise-in-duced myocardial ischemia and plasma endothelin-1 concentrations in patients with stable angina［J］. Clin Chim Acta, 2005, 354(1-2):205-208.
［4］Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among785 patientswith primary hypercholesterolemia［J］. Circulation, 2001, 103（9）:1191-1193.
［5］Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein for the cholesterol and recurrentEvents (CARE) investigators［J］. Circulation, 1999, 100（3）:230-235.
［6］Diomede L, Albani D, Sottocorno M, et al. In vivo anti-inflammatory effect of statins ismediatedby nonsterolmevalonate products［J］. Arterioscler Thromb Vasc Bio, 2001, 21（8）:1327-1332.
［7] Spencer FA, Allegrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE investigators［J］. Ann Intern Med, 2004, 140(7):923-924.
［8］Li JJ, Fang CH, Chen MZ, et al. Activation of NF-κB and associated with elevated C-reactive protein in patientswith unstable angina［J］. Heart Lung Circulation, 2004, 13（2）:173-178.
[9] Lefer AM, Campbell B, Shin YK, et al. Simvastatin preserves the ischemic reperfuse dmyocardium in normocholesterolemic rat hearts［J］. Circulation, 1999, 100（2）:178-184.
备注/Memo
- 备注/Memo:
- 收稿日期: 2010-01-29.作者简介：伏忠阳，副主任医师，硕士Email:fu1018@yahoo.com.cn
常用功能
统计/Statistics
- 摘要浏览/Viewed1263
- 评论/Comments
